| Literature DB >> 35273846 |
Zunaira Khan1, Ahmad Ammar Khattak2, Nawal Rafiq3, Anam Amin4, Mahwish Abdullah5.
Abstract
The clinical impact of the severe acute respiratory syndrome 2 (SARS-CoV-2) pandemic is growing, and vaccine-associated complications are becoming more evident. Although global vaccination against coronavirus disease 19 (COVID-19) is an outstanding accomplishment, safety concerns and adverse outcomes are also emerging that need to be addressed promptly. The most reported side effects of the COVID-19 vaccine include fever, myalgia, headache, and injection site reactions. Acute transverse myelitis (ATM) and interstitial lung disease (ILD) following the CoronaVac vaccine are rarely reported. We report a case of ILD followed by acute myelopathy in a female who presented with dyspnea, cough, and fever after the second dose of the COVID-19 vaccine. On the third day of admission, she developed paresthesia and bilateral upper and lower limb weakness. She was diagnosed with ILD and ATM due to the COVID-19 vaccine based on imaging and detailed investigations after ruling out all possible causes. Her neurological and respiratory manifestations improved gradually after starting intravenous methylprednisolone.Entities:
Keywords: acute myelopathy; acute transverse myelitis (atm); covid 19 vaccine; interstitial lung disease; vaccine adverse events
Year: 2022 PMID: 35273846 PMCID: PMC8901165 DOI: 10.7759/cureus.21875
Source DB: PubMed Journal: Cureus ISSN: 2168-8184